Perform Another (Advanced) Search

1.  Study Posting (5169) Trial #140858, Shingles, Newport News, VA
...tolerability of an investigational vaccine (ZOSTAVAX(TM)) that may prevent shingles in patients on chronic Corticosteroids therapy. Shingles (H. zoster) is the same virus that causes chickenpox. The virus can reappear ...
...Inclusion Criteria: Must be 60 years old or older. Must be taking long-term daily corticosteroid medication such as Prednisone, Deltasone, Medrol, Decadron, Cortef, Prelone. Patient Exclusion Criteria: Must not have ...
View Page

2.  Study Posting (77) Trial #140549, Systemic Lupus Erythematosus, Lake Success, NY
...18 years of age • Have a diagnosis of lupus (SLE) • Have been on lupus medication (corticosteroids, immunosuppressive drugs, or anti-malarias) for more than 30 days. Patient Exclusion Criteria You may ...
...the following within 30 days: A live vaccine; or A change in dose of a corticosteroid, other immunosuppressive/immunomodulatory agent, or anti-malarial agent • Have severe lupus kidney disease • Have active ...
View Page

3.  Study Posting (709) Trial #40288, Stasis Dermatitis, Stanford, CA
...have redness, itching, scaling, and swelling of the lower legs. The study medication contains a corticosteroid foam. We are seeking men and women volunteers over age 18 with mild to moderate ...
View Page

4.  Study Posting (4519) Trial #102320, Rheumatoid Arthritis, Stoke-on-Trent, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

5.  Study Posting (4519) Trial #97611, Rheumatoid Arthritis, Leeds, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

6.  Study Posting (4519) Trial #103507, Rheumatoid Arthritis, Chertsey, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

7.  Study Posting (4519) Trial #97589, Rheumatoid Arthritis, Cambridge, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

8.  Study Posting (4519) Trial #100863, Rheumatoid Arthritis, Birmingham, United Kingdom
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

9.  Study Posting (4519) Trial #100470, Rheumatoid Arthritis, Stockholm, Sweden
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

10.  Study Posting (4519) Trial #104298, Rheumatoid Arthritis, Goeteborg, Sweden
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

11.  Study Posting (4519) Trial #104087, Rheumatoid Arthritis, Sevilla, Spain
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

12.  Study Posting (4519) Trial #101517, Rheumatoid Arthritis, Santiago de Compostela, Spain
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

13.  Study Posting (4519) Trial #103517, Rheumatoid Arthritis, Merida, Spain
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

14.  Study Posting (4519) Trial #96930, Rheumatoid Arthritis, Madrid, Spain
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

15.  Study Posting (4519) Trial #98738, Rheumatoid Arthritis, La Laguna, Spain
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

16.  Study Posting (4519) Trial #100890, Rheumatoid Arthritis, Wroclaw, Poland
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

17.  Study Posting (4519) Trial #104212, Rheumatoid Arthritis, Warszawa, Poland
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

18.  Study Posting (4519) Trial #97839, Rheumatoid Arthritis, Lublin, Poland
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

19.  Study Posting (4519) Trial #100030, Rheumatoid Arthritis, Bialystok, Poland
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page

20.  Study Posting (4519) Trial #98716, Rheumatoid Arthritis, Auckland, New Zealand
...Summary: This study will assess the efficacy and safety of different treatment regimens of MabThera, corticosteroids and placebo, combined with methotrexate (MTX), in patients with active rheumatoid arthritis (RA). The anticipated ...
...Wk 24, Proportion of patients with an ACR20 response in the medium- and high-dose corticosteroid groups Safety: Adverse events, laboratory parameters Inclusion Criteria: • adult patients 18-80 years of age ...
View Page